Before the Move: Street says this stock may react to Merck’s PAH data

Jefferies analyst Eun Yang is positive on this stock ahead of Merck’s (MRK) data from its Phase 3 trial for sotatercept in pulmonary arterial hypertension, or PAH, which could potentially come this month. The analyst has… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3591588/-Before-the-Move-Street-says-this-stock-may-react-to-Mercks-PAH-data)

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire